The Broad Institute spinout will develop its CRISPR-based Sherlock platform for battlefield-ready diagnostics for infectious disease agents.
While the news of the BARDA contract drove a surge in T2's stock price, it was last month's NTAP decision that has company officials and analysts encouraged.
The DoD and VA-led initiative is moving beyond its initial focus on lung cancer to add analyses of multiple cancer types and a prospective, multisite study.
According to Science, the independent Jason advisory group to the US Department of Defense has lost its contract.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.
The two-year contract will be used to develop a portable prototype to quickly identify critical infectious pathogens considered threatening to war combatants.
The consortium aims to identify tuberculosis protein targets and corresponding small molecule inhibitors that can be used to develop drugs to shorten therapy duration.
The study aims to explore the "unique benefits and challenges" or incorporating genomic information into the routine care of active duty Air Force members.
The study being conducted under the Genomes2People umbrella will explore how best to introduce genetic information into the routine care of active duty service members.
Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.
University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.
NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.
In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.